Joseph McCracken

Joseph S.
McCracken is Director at REGiMMUNE Corp.
since 2015.
Director at Neuropore Therapies, Inc. since 2019.
Director at Modalis Therapeutics Corp.
since 2018.
Lead Independent Director at Savara, Inc. since 2019.
Director at Eos Therapies, Inc. Formerly Director at NewLink Genetics Corp., Aravas, Inc., Calliditas Therapeutics Suisse SA, Calliditas Therapeutics France SAS. Independent Director at Kindred Biosciences, Inc. from 2018 to 2021.
Independent Non-Executive Director at Nexvet Biopharma Plc from 2014 to 2017.
Director at Nexvet Australia Pty Ltd. from 2014 to 2015.
Independent Director at Lumos Pharma, Inc. from 2020 to 2024.
Director at Alkahest, Inc. from 2013 to 2020.
Vice President-Business Development at Genentech, Inc. from 2000 to 2009.
VP, Global Head-Business Development & Licensing at Roche Pharmaceuticals, Inc. from 2011 to 2013.
Vice President-Business Development at Aventis Pharmaceuticals, Inc. VP, Global Head-Business Development & Licensing at Hoffmann-La Roche, Inc. in 2013.
General Manager at Roche Diagnostics KK from 2009 to 2011.
Vice President-Business Development at Rhone-Poulenc Rorer SA from 1997 to 2000.
Education includes undergraduate (1976), graduate (1977), and doctorate (1980) degrees from The Ohio State University.